SHR-1918 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, Clin Pharmacokinet) - P1 | "SHR-1918 was well tolerated and showed promising efficacy in lipid reduction among healthy subjects."

Clinical • Journal • Dyslipidemia • ANGPTL3

Efficacy And Safety Of SHR-1918, An Angiopoietin-like 3 Monoclonal Antibody, In Combination With Lipid-lowering Therapy In Patients With Suboptimally Controlled Hyperlipidemia: A Multicenter, Randomized, Double Blind, Placebo-controlled Phase 2 Trial - Xiaojie Xie (ACC 2025) - No abstract available

Clinical • Combination therapy • Late-breaking abstract • P2 data • Dyslipidemia • ANGPTL3

Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study. (PubMed, J Am Coll Cardiol) - P2 | "Based on standard lipid-lowering therapy, ANGPTL-3 inhibition with SHR-1918 further reduces LDL-C by 21.7% to 29.9% in patients at moderate or higher risk of ASCVD. These additional reductions are both dose and dosing frequency dependent. (Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic; NCT06109831)."

Clinical • Journal • P2 data • Atherosclerosis • Cardiovascular • Dyslipidemia • ANGPTL3 • APOA1 • APOB • LPL

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - P3 | N=45 | Recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (clinicaltrials.gov) - P2 | N=44 | Active, not recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - P3 | N=45 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

New P3 trial • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study (ESC 2024) - P2 | "ConclusionsSHR-1918 was well-tolerated and showed promising efficacy in healthy subjects. A phase 2 study has initiated to evaluate SHR-1918 in hyperlipidemic patients (NCT06109831)."

Clinical • P1 data • Atherosclerosis • Cardiovascular • Dyslipidemia • ANGPTL3

Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (clinicaltrials.gov) - P2 | N=42 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

New P2 trial • Dyslipidemia

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic (clinicaltrials.gov) - P2 | N=335 | Active, not recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic (clinicaltrials.gov) - P2 | N=320 | Recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic (clinicaltrials.gov) - P2 | N=320 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

Combination therapy • New P2 trial

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

New P2 trial • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders

Safety and Tolerability of SHR-1918 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • APOA1 • APOB

Safety and Tolerability of SHR-1918 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

New P1 trial • APOA1 • APOB